To enable patients to race with the virus and the epidemic, companies developed effective drugs on the line, the regulator special affairs to allow its rapid approval of the market is obviously critical. Reporters learned on March 14, the State Drug Administration issued a notice, is carrying out clinical trials of new coronavirus pneumonia outbreak-related diseases of the drug injectable Cevilastat sodium has been approved by the fire line on the market. The reporter learned from the production of injectable seviraistat sodium Shanghai Huilun Jiangsu Pharmaceuticals was informed that seviraistat sodium is an old drug, in the 2003 SARS epidemic, seviraistat sodium has entered the stage of clinical research in our country and for the treatment of SARS-induced acute lung injury, and became the first to enter the clinical trial of the first after the launch of the country’s fast-track approval of the treatment of SARS drugs. In this sudden outbreak of neocoronavirus pneumonia, Ceviraxastat sodium was once again highly valued by the State Drug Administration and other departments, and was one of the five drugs approved to carry out clinical trials for neocoronavirus pneumonia outbreak-related diseases, and was included in the emergency review channel. Previously on February 21 in the “State Council Joint Prevention and Control Mechanism press conference”, Chen Shifei, deputy director of the State Drug Administration, said, “the State Drug Administration in accordance with the safety of the bottom line, evidence of efficacy, quality assurance, the review of the principle of routine, the approval of five drugs into the clinical trial, and the progress is now The progress has been relatively smooth. On the previous has basically completed the study, used for non-new crown pneumonia indications of drugs, where included in the scientific research and study group for the treatment of new crown pneumonia attack project, also launched a priority review and approval process, the special case approved for listing, for front-line doctors to choose to use under the premise of ensuring safety, the choice of entry into the clinical treatment program.” The manufacturer revealed that Cevilastat sodium this time is the first drug approved in China for the treatment of acute lung injury and acute respiratory distress syndrome accompanied by systemic inflammatory response syndrome. It is understood that acute respiratory distress syndrome is the respiratory system, mortality rate as high as 26 to 44%, SARS, the Middle East respiratory distress syndrome and influenza virus-induced pneumonia can lead to acute respiratory distress syndrome. In fact, the most common fatal complication in this global outbreak of C.pneumonia is acute respiratory distress syndrome (ARDS), which accounts for about 30% of the cases. A study just published in The Lancet showed that of the first 41 confirmed cases of the new coronavirus admitted to hospitals in Wuhan, nearly one-third of patients developed acute respiratory distress syndrome (29%), and six of them died. A related article published by Academician Zhong Nanshan and Professor Liu Zhigang on March 7 also showed that an analysis of the literature on retrospective studies of neocoronavirus pneumonia found that the proportion of patients entering ICUs in the whole country, Hubei Province, and non-Hubei Province were 11.5%, 21.9%, and 2.5%, respectively. Among the common complications, acute respiratory distress syndrome accounted for precisely the highest proportion. The reporter noted that the fire line approval of Cevilastat sodium is not without precedent. Previously in February this year, Hai Zheng Pharmaceutical production of Fapiravir also received conditional approval of the State Drug Administration listing, on the one hand, can be used for the treatment of influenza, but also available for sympathetic administration for the treatment of new coronavirus pneumonia. Source: Beijing Daily